Cannabis product testing

AUXLY REPORTS Q3 2023 FINANCIAL RESULTS

Retrieved on: 
Monday, November 13, 2023

Our Q3 results reflect the tireless efforts of our talented employees and their commitment to making incredible products that help people live happier lives.

Key Points: 
  • Our Q3 results reflect the tireless efforts of our talented employees and their commitment to making incredible products that help people live happier lives.
  • We are united in our mission, encouraged by our quarterly results and dedicated to building on those positive achievements."
  • Auxly maintained its position as a top 5 LP, by maintaining strength in sales of both Cannabis 1.0 and Cannabis 2.0 Products.
  • Please see the Company's MD&A for the three months and nine months ended September 30, 2023, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

AUXLY REPORTS Q2 2023 FINANCIAL RESULTS

Retrieved on: 
Monday, August 14, 2023

Hugo Alves, CEO of Auxly, commented: "The results for the second quarter of 2023 reflect our focus on simplifying and streamlining the business to improve operating efficiency and reduce costs.

Key Points: 
  • Hugo Alves, CEO of Auxly, commented: "The results for the second quarter of 2023 reflect our focus on simplifying and streamlining the business to improve operating efficiency and reduce costs.
  • Auxly maintained its position as a top 5 LP, by maintaining strength in sales of both Cannabis 1.0 and Cannabis 2.0 Products.
  • The Company successfully transitioned all functions previously conducted at its Auxly Ottawa facility to its Auxly Leamington facility, and is in the process of winding down and disposing of Auxly Ottawa's assets.
  • Please see the Company's MD&A for the three months and six months ended June 30, 2023, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

AUXLY REPORTS Q1 2023 FINANCIAL RESULTS

Retrieved on: 
Monday, May 15, 2023

For the period ended March 31, 2023, net revenues were $24.0 million as compared to $22.6 million during the same period in 2022.

Key Points: 
  • For the period ended March 31, 2023, net revenues were $24.0 million as compared to $22.6 million during the same period in 2022.
  • Net revenues included wholesale bulk flower sales of approximately $1.0 million during the first quarter of 2023.
  • The results for the first quarter of 2023 continued to build upon the gains made in the fourth quarter of 2022.
  • Please see the Company's MD&A for the three months ended March 31, 2023, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

AUXLY REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES OUTLOOK FOR 2023

Retrieved on: 
Friday, March 31, 2023

Hugo Alves, CEO of Auxly, commented: "The Canadian cannabis industry faced numerous challenges in 2022 and Auxly was not immune to their impacts.

Key Points: 
  • Hugo Alves, CEO of Auxly, commented: "The Canadian cannabis industry faced numerous challenges in 2022 and Auxly was not immune to their impacts.
  • Our efforts have yielded positive results, including our first significant wholesales of bulk dried flower from Auxly Leamington, improved net revenues and blended margins, and reductions in SG&A during the fourth quarter.
  • For the year ended December 31, 2022, net revenues were $94.5 million as compared to $83.8 million during the same period in 2021.
  • Please see the Company's MD&A for the three and twelves months ended December 31, 2022, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

Canada Cannabis Production Industry Report 2022 Featuring Tilray & Canopy Growth Corp - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022

The "Cannabis Production in Canada - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Production in Canada - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering.
  • Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
  • The Cannabis Production industry in Canada has blossomed over the five years to 2019 as a massive market was introduced into the industry, driving up revenue late during the period.
  • The Cannabis Production industry in Canada includes all companies licensed by Health Canada to cultivate, produce and sell products containing marijuana for medical and recreational consumption.

AUXLY REPORTS Q2 2022 FINANCIAL RESULTS

Retrieved on: 
Monday, August 15, 2022

FollowingtheacquisitionofAuxlyLeamingtoninNovember2021,theCompany recognizesgross profit or loss from Auxly Leamington as part of the costs of finished cannabis inventory sold only asproductissoldtotheCompany's customersafterbeingfurtherprocessed byAuxlyOttawaor Auxly Charlottetown.

Key Points: 
  • FollowingtheacquisitionofAuxlyLeamingtoninNovember2021,theCompany recognizesgross profit or loss from Auxly Leamington as part of the costs of finished cannabis inventory sold only asproductissoldtotheCompany's customersafterbeingfurtherprocessed byAuxlyOttawaor Auxly Charlottetown.
  • Prior to the acquisition of Auxly Leamington, the net operating results of Auxly Leamington were recorded in other income and expenses on an equity basis in proportion to the Company's ownership in the joint venture.
  • The net loss of $54.1 million through six months of 2022 includes the net impact of approximately $25.7 million related to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities during the first quarter of 2022.
  • Please see the Company's MD&A dated June 30, 2022, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

AUXLY REPORTS Q1 2022 FINANCIAL RESULTS

Retrieved on: 
Monday, May 16, 2022

Gross profits were impacted by the biological assets and inventory impairments of $5.0 million associated with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities as announced on February 7, 2022.

Key Points: 
  • Gross profits were impacted by the biological assets and inventory impairments of $5.0 million associated with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities as announced on February 7, 2022.
  • Following the acquisition of Auxly Leamington, the Company recognizes gross profit or loss from Auxly Leamington only as product is sold to the Company's customers after being further processed by Auxly Ottawa or Auxly Charlottetown.
  • Biological and inventory impairments of $0.7 million and $4.9 million respectively were attributable to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities.
  • Please see the Company's MD&A dated March 30, 2022, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

STEEP HILL, PIONEER OF U.S. CANNABIS TESTING, TO OPEN A LICENSED LAB IN VERMONT

Retrieved on: 
Wednesday, May 11, 2022

 , May 11, 2022 /PRNewswire/ -- Steep Hill, a leader in cannabis analytical testing, and the United States' first commercial cannabis lab, expands with a new licensee partner into the state of Vermont. In 2004, Vermont legalized cannabis for medicinal use and more recently in 2020, Vermont became the 11th state to approve of adult use sales. Licensee Steep Hill Vermont is the first analytics laboratory to receive pre-approval from the State of Vermont.

Key Points: 
  • In 2004, Vermont legalized cannabis for medicinal use and more recently in 2020, Vermont became the 11th state to approve of adult use sales.
  • Licensee Steep Hill Vermont is the first analytics laboratory to receive pre-approval from the State of Vermont.
  • Steep Hill Vermont is projected to support cannabis and hemp cultivation and processor customers by fall of 2022.
  • Prior to Steep Hill Vermont, Callie was the head of the Cannabis Product Development program with her former employer and consulted with cannabis brands across the US.

Tyson 2.0, Iconic Heavyweight Champion Mike Tyson's Cannabis Brand Continues Nationwide Expansion With Launch of Products in Delaware, Illinois and Washington D.C.

Retrieved on: 
Thursday, March 31, 2022

ORANGE COUNTY, Calif., March 31, 2022 /PRNewswire/ -- Tyson 2.0 ("The Company"), iconic boxer, entrepreneur and cannabis advocate Mike Tyson's cannabis brand, today announced that Tyson 2.0's premium range of cannabis products are now available at retailers across Delaware, Illinois and Washington D.C. This multi-state market launch, in partnership with Columbia Care, one of the largest and most experienced cultivators, manufacturers, and distributors of cannabis in the U.S., will bring Tyson 2.0 branded cannabis products including premium proprietary strains, flower, concentrates and consumables, to fans and consumers across all three regions. In addition to the markets announced today, Tyson 2.0's high-quality cannabis products are available in California, Colorado, Massachusetts, Michigan and Nevada with plans for more states coming online in Q2.

Key Points: 
  • Tyson 2.0 products are available for purchase at all three Columbia Care dispensaries in Delaware, located in Rehoboth Beach, Smyrna, and Wilmington.
  • Tyson 2.0's premium products are also available in Illinois at Columbia Care's Chicago location and select retail locations of Zen Leaf, Windy City, and Ascend.
  • "Each of our markets are clamoring for the Tyson 2.0 products, with lines around the blocks when we launch.
  • Tyson 2.0 is a premier cannabis company formed with legendary boxer, entrepreneur and icon Mike Tyson.

SC Labs is First to Create a Hemp Testing Panel that Covers a Range of Contaminants at a National Level

Retrieved on: 
Monday, June 14, 2021

According to SC Labs CEO Jeff Gray, "As an industry, we've been advocating for national, standardized, and transparent testing regulations for years now.

Key Points: 
  • According to SC Labs CEO Jeff Gray, "As an industry, we've been advocating for national, standardized, and transparent testing regulations for years now.
  • This new comprehensive testing panel covers a range of cannabinoids, pesticides, microbiological contaminants, mycotoxins, heavy metals, and residual solvents, combining each individual state's requirements, thus meeting the highest regulatory bar.
  • SC Labs offers comprehensive solutions for cannabis and hemp testing.
  • The test meets the hemp testing standards of states with requirements in terms of action limits and analytes for contaminants including pesticides, heavy metals, microbiology, mycotoxins, residual solvents, and water activity.